Osteoporosis Research Articles

Photobiomodulation therapy at 650 nm enhances osteogenic differentiation of osteoporotic bone marrow mesenchymal stem cells through modulating autophagy

BackgroundPhotobiomodulatiom therapy (PBMT) has biostimulatory effects on bone marrow mesenchymal stem cells (BMSCs), which takes a pivotal role in maintaining bone mass and avoiding osteoporosis (OP). Autophagy is an important regulator for cell survival and homeostasis. Previous researchers found that BMSCs derived from osteoporotic rats (OP-BMSCs) were with the feature of reduced osteogenic differentiation and autophagy dysfunction. However, the potential regulation of PBMT in osteogenic differentiation of OP-BMSCs and its underling relationship with autophagy remain unclear. Methods650 nm red light-emitting diode (LED) was selected to initiate PBMT effects. The isolation and culture of OP-BMSCs were implemented after the establishment of the OP rat model. Firstly, the optimal dose of LED was screened on OP-BMSCs by CCK-8. Meanwhile, the osteogenic and mineralization activities were studied through the detection of Alkaline phosphatase (ALP) and alizarin red S (ARS). Then, the levels of osteogenesis and autophagy were investigated via western blot and immunofluorescence staining. Finally, the autophagy inhibitor 3-MA was applied to illustrate the underlying mechanism of the osteogenic effect of PBMT on OP-BMSCs. ResultsFirstly, the optimal dose of 6 J/cm2 LED was selected in the subsequent experiments according to CCK-8. Then, the ALP activity and the mineralization ability of OP-BMSCs were obviously increased by PBMT. Meanwhile, Runx-2, OCN and OPN were significantly upregulated in LED group. Furthermore, the expressions of autophagic proteins were significantly increased in LED group by immunofluorescence staining and western blot assay. At last, the promoted effects of PBMT on osteogenic differentiation in OP-BMSCs were distinctly reversed via inhibiting autophagy. ConclusionOur research illustrated that 650 nm LED could improve osteogenic differentiation of OP-BMSCs, suggesting a potential correlation between PBMT-mediated activation of autophagy and promotion of osteogenic differentiation.

Chlorogenic Acid-Cucurbit[n]uril Nanocomplex Delivery System: Synthesis and Evaluations for Potential Applications in Osteoporosis Medication.

Based on nanomedicine strategies, this study employed cucurbit[7]uril (Q[7]) as the macromolecular carrier to synthesize nanocomplex drug delivery system for chlorogenic acid (CGA). The nanocomplex drug delivery system is intended to overcome the unsatisfactory biocompatibility and bioavailability of CGA and realizing its potential role in long-term osteoporosis (OP) medication. The nanocomplex was synthesized by the reflux stirring method. The chemical structure of the nanocomplex was characterized by Fourier transform infrared spectroscopy (FTIR), thermogravimetric analysis (TGA), X-ray diffraction analysis (XRD), UV-visible spectrophotometry (UV-vis), zeta potential analysis and transmission electronic microscope (TEM). The Cell Counting Kit-8 (CCK-8) assay, Live/Dead staining assay, and cytoskeleton staining were conducted to testify the biocompatibility of the nanocomplex. The release assay, Ferric Reducing Ability of Plasma (Frap) assay and Reactive oxygen species (ROS) staining were implemented to evaluate the release profile of CGA as well as its remaining antioxidative levels. CGA and Q[7] formed hydrogen bonding through an exclusion interaction, with the binding ratio more than 1:1. The nanocomplex had a crystalline and spherical-like structure and improved thermal stability. The nanocomplex demonstrated better biocompatibility than free CGA. The release profile of CGA from the nanocomplex was much steadier, and 70% of CGA was released in 5 days. The CGA released from the nanocomplex maintained its antioxidative properties at high levels and effectively eliminated the accumulated ROS in MC3T3-E1 cells under oxidative stress. Q[7] has been demonstrated to be an ideal nanocarrier for CGA and the nanocomplex delivery system holds the potential for the long-term medication strategy of OP.

A duty to enhance? Genetic engineering for the human Mars settlement.

Humans living off-world will face numerous physical, psychological and social challenges and are likely to suffer negative health effects due to their lack of evolutionary adaptation to space environments. While some of the necessary adaptations may develop naturally over many generations, genetic technologies could be used to speed this process along, potentially improving the wellbeing of early space settlers and their offspring. With broad support, such a program could lead to significant genetic modification of off-world communities, for example, to limit radiation damage on body systems or prevent bone and muscle loss in reduced gravity conditions. Given the extreme stressors of living off-world, and the need to have a healthy workforce to support a fledgling human settlement, those in favour of using genetic technologies to enhance settlers might even claim there is a moral imperative to protect their health in the face of the unique threats of space travel, especially for children born in settlements who did not take on these risks voluntarily. For some, this might simply be an extension of procreative beneficence. However, ethical concerns arise regarding the risks of embracing a eugenicist agenda and the potential impacts on the rights of future settlers to refuse such genetic enhancements for themselves or their children.

Hyperparathyroidism in patients with low bone mineral density treated with zoledronic acid or denosumab

ObjectiveTo analyze the prevalence of hyperparathyroidism in patients treated with zoledronic acid (ZA) or denosumab, its relationship with other parameters and how it affects on bone mineral density (BMD) evolution. MethodsRetrospective observational study in patients with osteoporosis or osteopenia and high risk of fracture, who have received denosumab or ZA for at least two years. Patients diagnosed with hyperparathyroidism or glomerular filtration rate <30 mL/min at baseline visit were excluded from the study. ResultsA total of 90 patients were included.Ninety patients (ZA: 54.44%) were included.18.36% of ZA-treated patients had elevated PTH levels at some time compared to 36.58% denosumab-treated patients (p > 0.05). Patients with persistently elevated PTH were 6.13% in the AZ group and 19.51% in the denosumab group (p < 0.04).We found a statistically significant inverse association between elevated PTH levels, glomerular filtration rate (p = 0.007) and albumin-corrected calcium (p < 0.001). We did not find an association between hyperparathyroidism and BMD evolution. ConclusionsA high incidence of hyperparathyroidism was observed in patients treated with AZ and especially denosumab. Hyperparathyroidism correlated inversely with glomerular filtration rate and albumin-corrected calcium. Elevated PTH does not appear to affect short-term bone mineral density evolution.

Investigating the Prevalence of Hypercalciuria in Children Aged 2-16 Years With Asymptomatic Microscopic Hematuria in 2020 in Tehran Children's Medical Center.

The prevalence of hypercalciuria in children is 3%-10% globally and up to 35% in the United States. Hypercalciuria in children has many presentations; it causes different metabolic disorders and can negatively affect a child's growth. It also increases the risk of low bone mineral density and urinary tract infections. In addition, it is the most widespread cause of persistent microscopic hematuria. Changes in the diet and medications in cases of advanced stage can be useful to prevent further complications. This study aimed to determine the prevalence of hypercalciuria and to investigate its relationship with different factors in children aged 2-16 years with asymptomatic microscopic hematuria in 2020 in the Children's Medical Center hospital. This retrospective cross-sectional study was performed in a population of children aged 2-16 years old with asymptomatic microscopic hematuria who were referred to the Children's Medical Center clinic in 2020. Data such as age, sex, serum creatinine level, and proteinuria were extracted from the patient's medical records, and their relationship with hypercalciuria was analyzed using logistic regression analysis. According to the inclusion criteria, 166 children with asymptomatic microscopic hematuria (72 boys and 94 girls) were included in this study. The prevalence of hypercalciuria (ratio of random urine calcium to creatinine more than 0.2) in these patients was estimated at 25% with a confidence interval of 18%-32%. In order of prevalence, the most common conditions accompanying microscopic hematuria were kidney stones, urinary tract infections, and proteinuria. The age of patients with hypercalciuria was 2 years younger on average. Each year of age increase and every 5 years of age increase between the ages of 2 and 16 years reduced the chance of hypercalciuria in this category of patients by 12% and 45%, respectively. Our findings also showed that children with a positive history of kidney stones were about 2.2 times more likely to have hypercalciuria than their counterparts, which is considered a medium effect size. Our results showed that hypercalciuria in children with hematuria is significantly related to younger age and a positive history of kidney stones.

Altered post-fracture systemic bone loss in a mouse model of osteocyte dysfunction

Abstract Femur fracture leads to loss of bone at uninjured skeletal sites, which may increase risk of subsequent fracture. Osteocytes, the most abundant bone cells, can directly resorb bone matrix and regulate osteoclast and osteoblast activity, but their role in systemic bone loss after fracture remains poorly understood. In this study we used a transgenic (TG+) mouse model that overexpresses human B-cell lymphoma 2 (BCL-2) in osteoblasts and osteocytes. This causes enhanced osteoblast proliferation, followed by disruption in lacunar-canalicular connectivity and massive osteocyte death by 10 weeks of age. We hypothesized that reduced viable osteocyte density would decrease the magnitude of systemic bone loss after femur fracture, reduce perilacunar remodeling, and alter callus formation. Bone remodeling was assessed using serum biomarkers of bone formation and resorption at 5 days post-fracture. We used micro-computed tomography, high resolution x-ray microscopy, mechanical testing, and Raman spectroscopy to quantify the magnitude of systemic bone loss, as well as changes in osteocyte lacunar volume, bone strength, and bone composition 2 weeks post-fracture. Fracture was associated with a reduction in circulating markers of bone resorption in non-transgenic (TG-) animals. TG+ mice exhibited high bone mass in the limbs, greater cortical elastic modulus and reduced post-yield displacement. After fracture, TG+ mice lost less trabecular bone than TG- mice, but conversely TG+ mice exhibited trends towards a lower yield point and reduced femoral cortical thickness after fracture, though these were not statistically significant. Lacunar density was greater in TG+ mice, but fracture did not alter lacunar volume in TG+ or TG- mice. These findings suggest that osteocytes potentially play a significant role in the post-traumatic systemic response to fracture, though the effects differ between trabecular and cortical bone.

Advanced Therapeutic Medicinal Products in Bone and Cartilage Defects.

The number of patients with functional loss of bone and cartilage tissue has shown an increasing trend. Insufficient or inappropriate conventional treatments applied for trauma, orthopedic diseases, or other bone and cartilage-related disorders can lead to bone and cartilage damage. This represents a worldwide public health issue and a significant economic burden. Advanced therapeutic medicinal products (ATMPs) proposed promising alternative therapeutic modalities by application of cell-based and tissue engineering approaches. Recently, several ATMPs have been developed to promote bone and cartilage tissue regeneration. Fifteen ATMPs, two related to bone and 13 related to cartilage, have received regulatory approval and marketing authorization. However, four ATMPs were withdrawn from the market for various reasons. However, ATMPs that are still on the market have demonstrated positive results, their broad application faced limitations. The development and standardization of methodologies will be a major challenge in the coming decades. Currently, the number of ATMPs in clinical trials using mesenchymal stromal cells or chondrocytes indicates a growing recognition that current ATMPs can be improved. Research on bone and cartilage tissue regeneration continues to expand. Cell-based therapies are likely to be clinically supported by the new ATMPs, innovative fabrication processes, and enhanced surgical approaches. In this study, we highlighted the available ATMPs that have been used in bone and cartilage defects and discussed their advantages and disadvantages in clinical applications.

Effect of Co-Loaded Vitamin D3 on Intravenous Injectable Raloxifene Delivery System

Owing to its promising advantages, including improved drug bioavailability and therapeutic efficiency at low doses and frequency, increased patient convenience and compliance, and prolonged storage life, nanomedicine has received heightened attention over conventional pharmaceuticals. Human serum albumin (HSA)-based nanoparticles have been used as drug carriers in injectable formulations, with great success and versatility. In this study, raloxifene and vitamin D3 were co-encapsulated in HSA-based nanoparticles (Ral/VitaD/HSA/PSS NPs) as an intravenously injected pharmaceutical formulation in order to enhance their availability in the body. The lyophilization–hydration method was utilized to develop the Ral/VitaD/HSA/PSS NPs. In addition, the characteristics and stability of the NP and the effect of the co-loading of vitamin D3 on raloxifene release in vitro and in vivo were discussed. The raloxifene and vitamin D3 molecules were successfully encapsulated and well dispersed in an amorphous state within Ral/VitaD/HSA/PSS NPs. The prepared Ral/VitaD/HSA/PSS NPs were lyophilized for long-term storage and were both biocompatible and hemocompatible, enhancing alkaline phosphtase activity in osteoblasts. Delivered via intravenous injection, Ral/VitaD/HSA/PSS NPs addressed the low bioavailability of raloxifene and vitamin D3 caused by oral administration, and improved their compatibility and residence time in the body. Overall, the established raloxifene–vitamin D3-co-loaded NPs may be a potential nanomedicine contender for treating postmenopausal osteoporosis.

Implants as Surveyed Crowns for Implant-Assisted Removable Partial Dentures: A Long-Term Case Series Study.

Long-term data on the use of implants as surveyed crowns for implant-assisted removable partial dentures (IARPDSCs) are limited. This study evaluated the long-term outcomes and assessed the risk factors associated with marginal bone loss (MBL) in IARPDSCs. A total of 51 implants were placed in 14 partially or fully edentulous patients and restored using IARPDSCs. Implant crowns or bridges served as abutments for the removable partial dentures (RPDs) to enhance their esthetics, comfort, and function. All patients attended regular follow-up appointments every 3-6 months for up to 12.5 years; these visits included professional cleaning and oral hygiene reinforcement. The collected data included patient demographics, treatment modality, arch restoration, Kennedy classification, RPD connection and retention design, opposing dentition, implant characteristics (location, connection type, and diameter), and any complications. The clinical assessments included plaque score, bleeding on probing, probing depth, marginal tissue recession, and keratinized mucosa width. Univariate and multivariate analyses were performed to identify factors influencing the MBL of implants in IARPDSCs. One implant failed during follow-up; thus, the implant survival rate was 98%. All patients were satisfied with their prostheses and reported only minor complications. Univariate analysis showed a significantly higher MBL in maxillary implants than in mandibular implants (P = .045). Multiple regression analysis revealed that bruxism (P = .002) and maxillary implants (P = .013) were significantly associated with a higher MBL. Female sex (P = .051) and anterior implants (P = .058) exhibited a trend toward an association with higher MBL. Within the limitations of this retrospective clinical study, IARPDSCs demonstrated predictable long-term success in carefully selected and well-maintained patients.

Treatment of Failed Anterior Instability Repair With DTA

This chapter explores the use of distal tibia allograft (DTA) for addressing glenoid bone deficiencies in revision surgery for anterior glenohumeral instability. Traditional approaches have often overlooked glenoid bone loss, which can negatively impact functional outcomes of a shoulder instability repair. The DTA offers a promising solution, effectively reconstructing the glenoid vault while minimizing damage to surrounding tissues when performed arthroscopically. This approach not only simplifies the surgical technique but also enhances stability when combined with soft tissue procedures. By allowing for personalized graft sizing, the DTA presents an adaptable option for various patients facing revision surgeries for anterior instability, making it a leading consideration in modern orthopaedic practice for the management of shoulder instability repair.

Custom Distal Humeral Replacement With Locked Flange To Manage Massive Distal Humeral Bone Loss In Re-Revision Total Elbow Arthroplasty

Custom Distal Humeral Replacement With Locked Flange To Manage Massive Distal Humeral Bone Loss In Re-Revision Total Elbow Arthroplasty

Damascenone Inhibits Osteoclastogenesis by Epigenetically Modulating Nrf2-Mediated ROS Scavenge and Counteracts OVX-Induced Osteoporosis

BackgroundBone formation and resorption regulate bone homeostasis. Excessive osteoclastogenesis enhances bone resorption and causes osteoporosis. Although medicines targeting osteoclast have been developed, these drugs have several side effects. Natural compounds have advantages in safety and efficiency, making them potential candidates for osteoporosis treatment. PurposeThis study aims to elucidate the role of damascenone (Dama) in osteoclastogenesis and osteoporosis. Study design and methodsTo demonstrate the effect of Dama on osteoclast differentiation and function, we performed multiple in vitro experiments including TRAP staining, F-actin staining, bone slice resorption assay, real-time PCR, and western bolt. Further, ROS detection, network pharmacology, microscale thermophoresis assay, and ChIP assay were conducted to elucidate the underlying molecular mechanism. Finally, the in vivo effects of Dama were verified using an ovariectomy induced osteoporosis mice model. ResultsDama inhibited RANKL-induced osteoclast differentiation and bone resorptive function in vitro. The expression of osteoclast-related genes and activation of MAPKs and NF-κB signaling in osteoclast were also attenuated by Dama. Meanwhile, Dama reduced intracellular ROS level via up-regulating Nrf2 expression. Network pharmacology demonstrated that HDAC2 is the potential direct target of Dama. Dama inhibited HDAC2 function and increased H3K27ac level of Nrf2, which induced Nrf2 expression and activated ROS scavenging enzymes. Inhibiting NRF2 or activating HDAC2 attenuated the effect of Dama on osteoclastogenesis. Finally, Dama injection suppressed in vivo osteoclastogenesis and ameliorated bone loss induced by OVX. ConclusionDama attenuates osteoclastogenesis by epigenetically modulating Nrf2 expression and ROS scavenge. This study provides evidence for Dama being a potential treatment for osteoporosis.

Imaging Pearls and Findings After Prior Shoulder Stabilization

This chapter emphasizes the significance of advanced imaging techniques, particularly MRI, in diagnosing the underlying causes of failed stabilization, such as recurrent labral tears, capsular deficiency, and glenoid bone loss. Key criteria for evaluating labral integrity post-surgery are discussed, alongside the importance of assessing the capsule and inferior glenohumeral ligament for signs of laxity or tears. Advanced MRI methodologies enable precise assessment of bony structures, while the interplay of imaging findings with history informs clinical decisions regarding revision surgery. Ultimately, integrating advanced imaging examination and surgical expertise can enhance patient outcomes and contribute to long-term shoulder functionality.

Pre-Shaped And Pre-Drilled Cortical Bone Allograft Provides Comparable Results To Coracoid Autograft In Treatment Of Instability With Glenoid Bone Loss

Pre-Shaped And Pre-Drilled Cortical Bone Allograft Provides Comparable Results To Coracoid Autograft In Treatment Of Instability With Glenoid Bone Loss

Contemporary Outcomes of Proximal Femoral Replacement as a Salvage Treatment in Nononcologic Severe Bone Loss

Contemporary Outcomes of Proximal Femoral Replacement as a Salvage Treatment in Nononcologic Severe Bone Loss

Deep learning method to automatically diagnose periodontal bone loss and periodontitis stage in dental panoramic radiograph.

Artificial intelligence (AI) could be used as an automatically diagnosis method for dental disease due to its accuracy and efficiency. This research proposed a novel convolutional neural network (CNN)-based deep learning (DL) ensemble model for tooth position detection, tooth outline segmentation, tooth tissue segmentation, periodontal bone loss and periodontitis stage prediction using dental panoramic radiographs. The dental panoramic radiographs of 320 patients during the period January 2020 to December 2023 were collected in our dataset. All images were de-identified without private information. In total, 8462 teeth were included. The algorithms that DL ensemble model adopted include YOLOv8, Mask R-CNN, and TransUNet. The prediction results of DL method were compared with diagnosis of periodontists. The periodontal bone loss degree deviation between the DL method and ground truth drawn by the three periodontists was 5.28%. The overall PCC value of the DL method and the periodontists' diagnoses was 0.832 (P <​ 0.001). ​The ICC value was 0.806 (P <​ 0.001). The total diagnostic accuracy of the DL method was 89.45%. The proposed DL ensemble model in this study shows high accuracy and efficiency in radiographic detection and a valuable adjunct to periodontal diagnosis. The method has strong potential to enhance clinical professional performance and build more efficient dental health services. The DL method not only could help dentists for rapid and accurate auxiliary diagnosis and prevent medical negligence, but also could be used as a useful learning resource for inexperienced dentists and dental students.

Long-Term Recurrence Rates After Isolated Arthroscopic Bankart In Selected Patients Without Preoperative Bone Loss Versus Open Latarjet A Matched-Pair Analysis

Long-Term Recurrence Rates After Isolated Arthroscopic Bankart In Selected Patients Without Preoperative Bone Loss Versus Open Latarjet A Matched-Pair Analysis

Antiosteoporotic activity of nodakenetin, a coumarin compound from Angelica decursiva, by activation of the Wnt/β-catenin signaling pathway

Angelica decursiva (Umbelliferae) is a medicinal plant widely used to treat colds, coughs and fevers in Korea, Japan, and mainland China. The anti-inflammatory activity of nodakenetin, a furano-coumarin compound from A. decursiva, has been reported, although, the antiosteoporotic activity remains unknown. This study sought to investigate the antiosteoporotic activity and precise mechanism of action of nodakenetin in vitro cell culture and in vivo bone remodeling models. The transcriptional activity of nodakenetin on the Wnt signaling pathway was assessed using the TOPflash/FOPflash assay. The effect of nodakenetin on the osteoblast differentiation was measured using Alizarin red staining and alkaline phosphatase (ALP) activity. Western blotting and real-time RT-PCR were used to assess the effect of nodakenetin on the expression of markers related to Wnt/β-catenin pathway and osteoblast differentiation. The in vivo antiosteoporotic activity of nodakenetin was assessed using an ovariectomized (OVX)-induced bone loss mouse model. Nodakenetin activated the Wnt/β-catenin pathway through regulation of DKK1, β-catenin and other target proteins of the Wnt/β-catenin pathway in HEK293 and MC3T3-E1 cells. Nodakenetin induced the differentiation of MC3T3-E1 cells as shown by enhanced Alizarin red staining and ALP activity. Induction of osteoblast differentiation was related to upregulated expression of bone formation biomarkers such as bone morphogenic proteins and Runx2. Oral administration of nodakenetin in the OVX mouse model effectively protected the deterioration of bone microstructure in OVX mice. Nodakenetin exhibits antiosteoporotic activity in vitro and in vivo through the activation of the Wnt/β-catenin pathway and subsequent induction of osteoblast differentiation.

Role of the PGAM5-CypD mitochondrial pathway in methylglyoxal-induced bone loss in diabetic osteoporosis

Diabetic osteoporosis (DOP) is a skeletal complication with a high rate of disability. It results in a great burden to the patient's family and society. Methylglyoxal (MG) is a toxic by-product of the glycolytic process that occurs during diabetic conditions. It causes osteoblastic injury and con-tributes to the initiation and development of DOP. Disruption of mitochondrial homeostasis has been implicated as a cause of dysregulated osteo-blastogenesis, an essential step in bone formation. It is unclear whether mitochondrial dysfunction is involved in MG-induced osteoblast dysfunction. In this study, we showed that mitochondrial dysfunction contributes to MG-induced MC3T3-E1 cell apoptosis and impaired differentiation. A significant reduction of mitochondrial membrane potential (MMP) and ATP production occurred in MG-induced osteoblasts as well as increasing mitochondrial reactive oxygen species (mtROS) and intracellular Ca2+. Classical antioxidant N-Acetylcysteine (NAC) significantly attenuated mitochondrial dysfunction as well as osteoblast apoptosis and osteogenic differentiation damage induced by MG. More importantly, we found that activating phosphoglycerate mutase family member 5 (PGAM5) and cyclophilin D (CypD), which contributes to mitochondrial homeostasis, is involved in MG-induced osteoblast injury. Both PGAM5 and CypD knockdown effectively reversed osteoblast viability and function, whereas PGAM5 or CypD overexpression aggravated osteoblast injury caused by MG. Moreover, the result of co-transfection revealed that PGAM5 is an upstream signaling molecule of CypD. By constructing type I diabetes mouse models, we further found that the expression of PGAM5 and CypD were both increased in the femur along with a reduction of ATP and increased TUNEL-positive cells. These results, for the first time, suggest that MG-induced mitochondrial dysfunction induces osteoblast injury through the PGAM5-CypD pathway. This study provides insight into the prevention and treatment of DOP. Lay summaryThis study highlights the role of mitochondria in regulating osteoblast viability and function under conditions of diabetic osteoporosis (DOP). We found that the PGAM5-CypD mitochondrial pathway is activated following glycolytic by-product methylglyoxal (MG) treatment, which contributes to mitochondrial dysfunction and osteogenic dysfunction. This mechanism implicates mitochondria as a potential therapeutic target for osteoporosis.

The Potential Risk: Evaluation of HgA1c Levels Prior to Dental Implant Surgery in Patients without a Diagnosis of Diabetes Mellitus.

Diabetes Mellitus (DM) poses a significant global health concern, with approximately one in two affected individuals remaining undiagnosed. The failure to diagnose or inadequately control DM can lead not only to systemic complications but also to decreased dental implant survival rates, increased marginal bone loss, and increased susceptibility to peri-implantitis. This study aims to evaluate glycated hemoglobin (HbA1c) levels in patients who have not been diagnosed with DM but exhibit oral DM symptoms prior to dental implant surgery. This study was designed as a retrospective cohort. It was conducted on patients who previously presented to the Department of Oral and Maxillofacial Surgery for dental implant surgery and had not been diagnosed with DM. The inclusion criteria included the need for dental implants and augmentation, presence of oral DM symptoms, and having blood tests that included HbA1c. Patients with a prior diagnosis of DM were excluded from the study. A retrospective analysis was conducted on data from 253 patients who applied for dental implant surgery. Among them, 72 patients underwent HbA1c levels assessment through blood tests. Patients with previously uncontrolled DM (n:21) and those whose blood tests were performed at different institutions (n:8) were excluded from the study. Consequently, the study encompassed a cohort of 43 patients. Among the participants, 55% were female and 45% were male. The HbA1c values of the patients ranged from 5.1 to 10.9, with an average value of 6.57±1.44. Of the patients, 41.8% were diagnosed with DM, 30.2% were prediabetic (preDM), and 27.9% did not receive any diagnosis. There was no statistically significant relationship between the combinations of xerostomia, delayed wound healing, oral infection, burning sensation in the mouth, periodontitis, and dental caries with HbA1c levels (p>0.05). In this study, patients presenting to the clinic for dental implant surgery were directed based on oral symptom findings, and the rates of diagnosed DM and preDM were determined to be 7.11% and 5.14%, respectively. Considering the negative effects and prevalence of uncontrolled DM, it may be recommended to assess the HbA1c levels in patients with oral symptoms before dental implant surgery.